Cycloguanil

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Cycloguanil
Accession Number
DB14763
Type
Small Molecule
Groups
Approved
Description

Cycloguanil is the active metabolite of proguanil.

Structure
Thumb
Synonyms
  • CGT
  • Chlorguanide triazine
  • Cycloguanilum
  • Cycloguanyl
External IDs
BN-24-10 / BN2410 / WR 5473
Product Ingredients
IngredientUNIICASInChI Key
Cycloguanil embonateTCO0SY4N3D609-78-9LUNRMKZYOGNOTR-UHFFFAOYSA-N
Categories
UNII
26RM326WVN
CAS number
516-21-2
Weight
Average: 251.715
Monoisotopic: 251.09377318
Chemical Formula
C11H14ClN5
InChI Key
QMNFFXRFOJIOKZ-UHFFFAOYSA-N
InChI
InChI=1S/C11H14ClN5/c1-11(2)16-9(13)15-10(14)17(11)8-5-3-7(12)4-6-8/h3-6H,1-2H3,(H4,13,14,15,16)
IUPAC Name
1-(4-chlorophenyl)-6,6-dimethyl-1,6-dihydro-1,3,5-triazine-2,4-diamine
SMILES
CC1(C)N=C(N)N=C(N)N1C1=CC=C(Cl)C=C1

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
(6R)-Folinic acidThe therapeutic efficacy of Cycloguanil can be decreased when used in combination with (6R)-Folinic acid.
(6S)-5,6,7,8-tetrahydrofolic acidThe therapeutic efficacy of Cycloguanil can be decreased when used in combination with (6S)-5,6,7,8-tetrahydrofolic acid.
AcepromazineThe risk or severity of QTc prolongation can be increased when Cycloguanil is combined with Acepromazine.
AceprometazineThe risk or severity of QTc prolongation can be increased when Cycloguanil is combined with Aceprometazine.
AcetophenazineThe risk or severity of QTc prolongation can be increased when Cycloguanil is combined with Acetophenazine.
AlimemazineThe risk or severity of QTc prolongation can be increased when Cycloguanil is combined with Alimemazine.
ArtemetherThe risk or severity of QTc prolongation can be increased when Cycloguanil is combined with Artemether.
BL-1020The risk or severity of QTc prolongation can be increased when Cycloguanil is combined with BL-1020.
ButaperazineThe risk or severity of QTc prolongation can be increased when Cycloguanil is combined with Butaperazine.
ChlorproethazineThe risk or severity of QTc prolongation can be increased when Cycloguanil is combined with Chlorproethazine.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

References

General References
Not Available
External Links
Human Metabolome Database
HMDB0060974
ChemSpider
8697
BindingDB
18792
ChEBI
135029
ChEMBL
CHEMBL747
ZINC
ZINC000000001233
PDBe Ligand
1CY
Wikipedia
Cycloguanil
ATC Codes
P01BB02 — Cycloguanil embonate
PDB Entries
3irm / 3irn / 3um6 / 3um8 / 4kne / 6hnc / 6nnh

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.246 mg/mLALOGPS
logP1.06ALOGPS
logP1.7ChemAxon
logS-3ALOGPS
pKa (Strongest Acidic)16.13ChemAxon
pKa (Strongest Basic)8.18ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area80 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity68.84 m3·mol-1ChemAxon
Polarizability25.51 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as aminotriazines. These are organic compounds containing an amino group attached to a triazine ring.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Triazines
Sub Class
Aminotriazines
Direct Parent
Aminotriazines
Alternative Parents
Chlorobenzenes / Aryl chlorides / 1,3,5-triazines / Guanidines / Propargyl-type 1,3-dipolar organic compounds / Carboximidamides / Azacyclic compounds / Organopnictogen compounds / Organochlorides / Imines
show 1 more
Substituents
Aminotriazine / Chlorobenzene / Halobenzene / Aryl chloride / Aryl halide / Monocyclic benzene moiety / 1,3,5-triazine / Benzenoid / Guanidine / Azacycle
show 11 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
Not Available

Drug created on May 01, 2019 09:47 / Updated on March 02, 2020 00:02

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates